Proactive Investors
16 Jan 2026, 14:24 UTC · 42w ago
Verdict
Headline takes no side. We score ATAI +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 89% of ticker scores this week
Scored by the NIS engine · methodology.
Search tags
What the story claims
4 claims · scored −1 bearish … +1 bullish
Both 8 mg and 12 mg single doses of BPL-003 demonstrated statistically significant, rapid, and sustained antidepressant effects in a Phase 2b trial for treatment-resistant depression.
More positive than 99% of claims this week
Both active dose levels of BPL-003 were generally well-tolerated in the Phase 2b trial.
Continue reading
5 related stories
More positive than 85% of claims this week
The BPL-003 Phase 2b results were selected for the prestigious ACNP Hot Topics Session, supporting further evaluation in later-stage clinical development.
More positive than 63% of claims this week
Preclinical data presented showed 5-MeO-DMT has potential neuroplasticity-related mechanisms of action relevant to treating mood disorders.
More positive than 42% of claims this week
Which stocks this story touches
More positive than 89% of ticker scores this week
The company presented successful Phase 2b clinical trial data and preclinical findings at a prestigious medical conference.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
2h ago
+98.1%
Price agrees with the score
$7.35 vs $3.71 close before publication (Jan 15) · not market-adjusted
ATAI chart →
